IL130994A0 - Use of 1-[4-(3- trifluoromethylphenyl)- 1,2,3,6-tetrahydropyrid- 1-yl]-2- (6,7-dimethoxynapth-2- yl) ethane for preparing medicines for the treatment of cerebral and neuronal disorders - Google Patents

Use of 1-[4-(3- trifluoromethylphenyl)- 1,2,3,6-tetrahydropyrid- 1-yl]-2- (6,7-dimethoxynapth-2- yl) ethane for preparing medicines for the treatment of cerebral and neuronal disorders

Info

Publication number
IL130994A0
IL130994A0 IL13099497A IL13099497A IL130994A0 IL 130994 A0 IL130994 A0 IL 130994A0 IL 13099497 A IL13099497 A IL 13099497A IL 13099497 A IL13099497 A IL 13099497A IL 130994 A0 IL130994 A0 IL 130994A0
Authority
IL
Israel
Prior art keywords
dimethoxynapth
tetrahydropyrid
trifluoromethylphenyl
cerebral
ethane
Prior art date
Application number
IL13099497A
Other languages
English (en)
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of IL130994A0 publication Critical patent/IL130994A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IL13099497A 1997-02-03 1997-02-03 Use of 1-[4-(3- trifluoromethylphenyl)- 1,2,3,6-tetrahydropyrid- 1-yl]-2- (6,7-dimethoxynapth-2- yl) ethane for preparing medicines for the treatment of cerebral and neuronal disorders IL130994A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/FR1997/000202 WO1998033502A1 (fr) 1997-02-03 1997-02-03 Utilisation du 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux

Publications (1)

Publication Number Publication Date
IL130994A0 true IL130994A0 (en) 2001-01-28

Family

ID=9502506

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13099497A IL130994A0 (en) 1997-02-03 1997-02-03 Use of 1-[4-(3- trifluoromethylphenyl)- 1,2,3,6-tetrahydropyrid- 1-yl]-2- (6,7-dimethoxynapth-2- yl) ethane for preparing medicines for the treatment of cerebral and neuronal disorders

Country Status (11)

Country Link
EP (1) EP0954311A1 (cs)
JP (1) JP2001511141A (cs)
AU (1) AU1607397A (cs)
CA (1) CA2279326A1 (cs)
CZ (1) CZ275399A3 (cs)
EE (1) EE9900332A (cs)
HU (1) HUP0000767A3 (cs)
IL (1) IL130994A0 (cs)
IS (1) IS5117A (cs)
TR (1) TR199901722T2 (cs)
WO (1) WO1998033502A1 (cs)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6272180B1 (en) * 1997-11-21 2001-08-07 Sharp Laboratories Of America, Inc. Compression and decompression of reference frames in a video decoder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
EP0954311A1 (fr) 1999-11-10
CZ275399A3 (cs) 1999-12-15
CA2279326A1 (fr) 1998-08-06
EE9900332A (et) 2000-02-15
AU1607397A (en) 1998-08-25
WO1998033502A1 (fr) 1998-08-06
TR199901722T2 (xx) 2000-08-21
HUP0000767A3 (en) 2000-10-30
IS5117A (is) 1999-07-15
JP2001511141A (ja) 2001-08-07
HUP0000767A2 (hu) 2000-09-28

Similar Documents

Publication Publication Date Title
NO20004915L (no) Transdermalt terapeutisk system som inneholder en D2-agonist og som tilveiebringes for behandling av Parkinsons sykdom og en fremgangsmÕte for dets fremstilling
IL136461A0 (en) Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
HUP0102656A3 (en) N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders and medicaments containing them
SI1185272T1 (en) Novel use of 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania
HUP9701193A3 (en) Use of n-(4-aryl-thiazol-2-yl)-sulfonamide derivatives for the preparation of pharmaceutical compositions treating neurological disorders, new derivatives, process for their preparation and pharmaceutical compositions containing them
ZA200107689B (en) 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
IL112895A (en) Pharmaceutical compositions for the treatment of obsessive-compulsive disorders comprising 5-HT2 antagonists
AP2001002102A0 (en) Pharmaceutical agents for the treatment of parkinson's disease and adhd and microadenomas
HUP0000963A3 (en) The use of levobupivacaine in paediatric surgery
HUP0000873A3 (en) The use of levobupivacaine in facial surgery
HUP9802945A3 (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
HUP0003428A3 (en) Use of leptin antagonists for the treatment of diabetes
ZA988095B (en) New peptide mimetics for the treatment of bone metabolic disorders, methods for their production, and drugs containing these compounds.
NZ502495A (en) Use of a specific antagonist of 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of sleep apnoea syndrome
IL150289A0 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
IL130994A0 (en) Use of 1-[4-(3- trifluoromethylphenyl)- 1,2,3,6-tetrahydropyrid- 1-yl]-2- (6,7-dimethoxynapth-2- yl) ethane for preparing medicines for the treatment of cerebral and neuronal disorders
HUP0104701A3 (en) 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders and medicaments containing the compounds
HUP9802736A3 (en) Use of 1,4-dihydropyridine derivatives for the preparation of medicament for the prevention and therapy of atherosclerotic degradation in the arterial walls
NO993728D0 (no) Anvendelse av 1-[4-(3-trifluormeylfenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimetoksynaft-2yl)etan for fremstilling av medikamenter for behandling av cerebrale og nevronale forstyrrelser
IL129647A0 (en) Substituted 4-(6-fluoro-(1H)-indol-3-YL)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders
FR2800589B1 (fr) Fauteuil articule a usage medical, pour handicapes et pour le relaxation
PL334942A1 (en) Application of 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1-il]-2-(6,7-dimethoxynapht-2-yl) ethane in production of drugs predestined to treat cerebral and neuronic diseases
PT1011678E (pt) Utilização de mecamilamina para o tratamento de perturbações neuropsiquiátricas responsivas à nicotina.
BR9714486A (pt) Utilização de 1-[4-(3-trifluorometilfenil)- 1,2,3,6-tetra-hidropirid-1-il]-2-(6,7-dimetoxinaft-2-il) etano